Updated guide for the management of malignant hyperthermia

作者: Sheila Riazi , Natalia Kraeva , Philip M. Hopkins

DOI: 10.1007/S12630-018-1108-0

关键词:

摘要: This continuing professional development module aims to prepare anesthesiologists for the timely recognition and management of a malignant hyperthermia (MH) reaction, which is crucial averting its life-threatening complications ultimately patient’s survival. Malignant genetic disorder skeletal muscle cells affecting myoplasmic calcium homeostasis. It can present with nonspecific signs hypermetabolic be fatal if treatment, including administration dantrolene sodium, not implemented promptly. Rapid evaluation rejection alternative diagnoses lead prompt diagnosis treatment therefore will significantly reduce complications, renal failure, cardiac dysfunction, disseminated intravascular coagulation, death. After patients should observed minimum 24 hr because possibility recrudescence. As it condition, survivors their family members referred specialized MH centre further testing counselling. The risk dying from has increased over past few years. A knowledgeable anesthesiologist who diligent attentive recognize an impending reaction treat promptly avoid this deadly condition.

参考文章(32)
Helle Ørding, Diana Bendixen, The Incidence of Malignant Hyperthermia in Denmark Anesthesia & Analgesia. ,vol. 64, pp. 21- 24 ,(1996) , 10.1007/978-4-431-68346-9_2
L. Heytens, P. Forget, J. L. Scholtès, F. Veyckemans, The changing face of malignant hyperthermia: Less fulminant, more insidious Anaesthesia and Intensive Care. ,vol. 43, pp. 506- 511 ,(2015) , 10.1177/0310057X1504300415
Sheila Riazi, Natalia Kraeva, Sheila M. Muldoon, James Dowling, Clara Ho, Maria-Alexandra Petre, Jerome Parness, Robert T. Dirksen, Henry Rosenberg, Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference Canadian Journal of Anesthesia/Journal canadien d'anesthésie. ,vol. 61, pp. 1040- 1049 ,(2014) , 10.1007/S12630-014-0227-5
Rachel Robinson, Philip Hopkins, Antonella Carsana, Hermann Gilly, Jane Halsall, Luc Heytens, Gunilla Islander, Karin Jurkat-Rott, Clemens Müller, Marie-Anne Shaw, Several interacting genes influence the malignant hyperthermia phenotype Human Genetics. ,vol. 112, pp. 217- 218 ,(2003) , 10.1007/S00439-002-0864-6
PM Hopkins, H Rüffert, MM Snoeck, T Girard, KPE Glahn, FR Ellis, CR Müller, A Urwyler, European Malignant Hyperthermia Group, O Bandschapp, R Gillies, V Glauber, L Heytens, G Islander, W Klingler, B Kraft, R Krivosic-Horber, N Pollock, F Schuster, H Silva, V Sorrentino, N Street, V Tegazzin, I Tzanova, European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility BJA: British Journal of Anaesthesia. ,vol. 115, pp. 531- 539 ,(2015) , 10.1093/BJA/AEV225
James M. Burkman, Karen L. Posner, Karen B. Domino, Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology. ,vol. 106, pp. 901- 906 ,(2007) , 10.1097/01.ANES.0000265148.86566.68
Eric J. Horstick, Jeremy W. Linsley, James J. Dowling, Michael A. Hauser, Kristin K. McDonald, Allison Ashley-Koch, Louis Saint-Amant, Akhila Satish, Wilson W. Cui, Weibin Zhou, Shawn M. Sprague, Demetra S. Stamm, Cynthia M. Powell, Marcy C. Speer, Clara Franzini-Armstrong, Hiromi Hirata, John Y. Kuwada, Stac3 is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy Nature Communications. ,vol. 4, pp. 1952- 1952 ,(2013) , 10.1038/NCOMMS2952
Kathryn M. Stowell, DNA Testing for Malignant Hyperthermia Anesthesia & Analgesia. ,vol. 118, pp. 397- 406 ,(2014) , 10.1213/ANE.0000000000000063
Eric B. Rosero, Adebola O. Adesanya, Carlos H. Timaran, Girish P. Joshi, Trends and Outcomes of Malignant Hyperthermia in the United States, 2000 to 2005 Anesthesiology. ,vol. 110, pp. 89- 94 ,(2009) , 10.1097/ALN.0B013E318190BB08